Scynexis (SCYX) Other Non-Current Assets (2013 - 2026)
Scynexis' (SCYX) quarterly Other Non-Current Assets came in at $109000.0 in Q2 2026, down 73.86% on a YoY basis from $417000.0 in Q2 2025, and little changed quarter-over-quarter from $109000.0 in Q1 2026.
Analysis
Scynexis (SCYX) Other Non-Current Assets (2013 - 2026) Analysis & Trends
Scynexis (SCYX) has reported Other Non-Current Assets for 14 consecutive years, with $109000.0 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Other Non-Current Assets fell 73.86% year-over-year to $109000.0; the trailing twelve-month figure through Jun 2026 stood at $109000.0 (down 73.86% YoY), and the FY2025 full-year result was $533000.0, up 27.82% from the prior year.
- Other Non-Current Assets steadied at $109000.0 in Q2 2026 per SCYX's latest filing, from $109000.0 in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $7.4 million in Q1 2023 and bottomed at $109000.0 in Q1 2026.
- Historically, Other Non-Current Assets has averaged $1.8 million across 5 years, with a median of $417000.0 in 2024.
- The sharpest annual moves came in 2022 and 2024: Other Non-Current Assets soared 701.01% in 2022, then slumped 97.65% in 2024.
- Over 5 years, Other Non-Current Assets stood at $5.5 million in 2022, then sank by 96.82% to $175000.0 in 2023, then jumped by 138.29% to $417000.0 in 2024, then advanced by 27.82% to $533000.0 in 2025, then plunged by 79.55% to $109000.0 in 2026.
- According to Business Quant data, Other Non-Current Assets over the past three periods registered $109000.0, $109000.0, and $533000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 12.98 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | 4.75 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 1.25 Bn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 2.31 Bn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | 124.00 Mn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | 618.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 65.13 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | 831.80 Mn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | 29.59 Mn |
| 10 | Scynexis | 58.41 Mn | -56.29 Mn | - | 109,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 109,000.00 |
| Mar 31, 2026 | 109,000.00 |
| Dec 31, 2025 | 533,000.00 |
| Sep 30, 2025 | 417,000.00 |
| Jun 30, 2025 | 417,000.00 |
| Mar 31, 2025 | 417,000.00 |
| Dec 31, 2024 | 417,000.00 |
| Sep 30, 2024 | 187,000.00 |
| Jun 30, 2024 | 175,000.00 |
| Mar 31, 2024 | 175,000.00 |
| Dec 31, 2023 | 175,000.00 |
| Sep 30, 2023 | 164,000.00 |
| Jun 30, 2023 | 163,000.00 |
| Mar 31, 2023 | 7.44 Mn |
| Dec 31, 2022 | 5.51 Mn |
| Sep 30, 2022 | 5.08 Mn |
| Jun 30, 2022 | 6.08 Mn |
| Mar 31, 2022 | 5.54 Mn |
| Dec 31, 2021 | 6.24 Mn |
| Sep 30, 2021 | 1.37 Mn |